Study: NCT05431153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Description: A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Description: A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Description: A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.